LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT)

Q: What does CUSIP 539319301 represent in this 13F holders report?

CUSIP 539319301 is the security identifier for LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share in Q2 2025?

10 institutional investors reported LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 539319301

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 2,666,933
Total 13F shares: 163,636
Share change: -136,375
Total reported value: $148,054
Price per share: $0.90
Number of holders: 10
Value change: -$163,058
Number of buys: 6
Number of sells: 4

Quarterly Holders Quick Answers

What is CUSIP 539319301?
CUSIP 539319301 identifies LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 539319301:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Glenn Krinsky	3/4/5	10%+ Owner	— class O/S missing	1,474,998	$3,702,245	—	17 Dec 2021	3/4/5
Gil Schwartzberg	3/4/5	Director, 10%+ Owner	— class O/S missing	1,176,388	$2,952,733	—	31 Dec 2021	3/4/5
INTRACOASTAL CAPITAL, LLC	13D/G	Mitchell P. Kopin	5%	138,763	$181,780	$0	11 Feb 2025	13D/G
Orca Capital AG	13D/G	—	4.5%	120,012	$157,216	-$127,568	14 Feb 2025	13D/G
FNY Investment Advisers, LLC	13F	Company	4%	107,000	$129,000	—	31 Mar 2025	13F
HighTower Advisors, LLC	13F	Company	3.7%	99,432	$120,313	—	31 Mar 2025	13F
Ethos Financial Group, LLC	13F	Company	0.93%	24,808	$50,353	—	31 Mar 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.92%	24,522	$29,672	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.86%	23,041	$27,879	—	31 Mar 2025	13F
Bastiaan Jeroen van der Baan	3/4/5	President and CEO, Director	— mixed-class rows	261,000 mixed-class rows	$27,610	—	03 Oct 2023	3/4/5
Yun Yen	3/4/5	Director	— mixed-class rows	16,895 mixed-class rows	$21,456	—	30 Jun 2025	3/4/5
Atlas Legacy Advisors, LLC	13F	Company	0.48%	12,707	$17,154	—	31 Mar 2025	13F
Regina Brown	3/4/5	Director	— class O/S missing	12,600	$16,002	—	30 Jun 2025	3/4/5
Rene Bernards	3/4/5	Director	— class O/S missing	10,662	$13,540	—	30 Jun 2025	3/4/5
Stephen J. Forman	3/4/5	Director	— mixed-class rows	9,421 mixed-class rows	$11,964	—	30 Jun 2025	3/4/5
UBS Group AG	13F	Company	0.31%	8,291	$10,032	—	31 Mar 2025	13F
SBI Securities Co., Ltd.	13F	Company	0.01%	189	$229	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	21	$25	—	31 Mar 2025	13F
John S. Kovach	3/4/5	President and CEO, Director	— mixed-class rows	221,100 mixed-class rows	—	—	06 Nov 2022	3/4/5
James Miser	3/4/5	Chief Medical Officer	— class O/S missing	200,000	—	—	06 Nov 2022	3/4/5
Robert N. Weingarten	3/4/5	Vice President and CFO	— class O/S missing	200,000	—	—	06 Nov 2022	3/4/5
Philip F. Palmedo	3/4/5	Director	— mixed-class rows	137,720 mixed-class rows	—	—	30 Jun 2022	3/4/5

Institutional Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) as of Q2 2025

As of 30 Jun 2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) was held by 10 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 163,636 shares. The largest 10 holders included HighTower Advisors, LLC, Ethos Financial Group, LLC, GEODE CAPITAL MANAGEMENT, LLC, Atlas Legacy Advisors, LLC, Tower Research Capital LLC (TRC), UBS Group AG, SBI Securities Co., Ltd., BANK OF AMERICA CORP /DE/, CLEAR STREET LLC, and RAYMOND JAMES FINANCIAL INC. This page lists 10 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.